Combined Lamivudine and Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Recurrence after Liver Transplantation: Long-Term Results
Article first published online: 11 JUL 2003
American Journal of Transplantation
Volume 3, Issue 8, pages 999–1002, August 2003
How to Cite
Dumortier, J., Chevallier, P., Scoazec, J.-Y., Berger, F. and Boillot, O. (2003), Combined Lamivudine and Hepatitis B Immunoglobulin for the Prevention of Hepatitis B Recurrence after Liver Transplantation: Long-Term Results. American Journal of Transplantation, 3: 999–1002. doi: 10.1034/j.1600-6143.2003.00191.x
- Issue published online: 11 JUL 2003
- Article first published online: 11 JUL 2003
- Received 11 February 2003, revised and accepted for publication 20 April 2003
- 13Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411–416., , , , .
- 19Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant Surg 1999; 5: 512–519., , et al.
- 25Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplant 2003; 9: 182–187., , et al.